Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage live biotherapeutics company that regularly issues news about its microbiome-based drug programs, regulatory interactions, and corporate developments. The company focuses on oral live biotherapeutics for medically vulnerable patient populations, particularly adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) and other high-risk groups.
News about Seres often centers on its lead investigational candidate SER-155, including Phase 1b clinical data showing a significant reduction in bacterial bloodstream infections, systemic antibiotic exposure, and febrile neutropenia in allo-HSCT patients compared with placebo. Updates also cover regulatory designations for SER-155, such as Breakthrough Therapy and Fast Track status, and detailed feedback from the U.S. Food and Drug Administration on the design of a planned Phase 2 study.
Investors and followers of MCRB can expect announcements on clinical trial progress, investigator-sponsored studies in areas like immune checkpoint inhibitor–related enterocolitis, and research presentations at major medical meetings. Seres also issues press releases on mechanistic publications for its live biotherapeutics, including VOWST™, and on data generated from its MbTx® platform that support its broader live biotherapeutic strategy.
In addition to R&D updates, Seres publishes news on cost-reduction actions, cash runway expectations, leadership changes, and efforts to secure capital or partnerships to advance its pipeline. For those tracking MCRB, this news feed provides a centralized view of program milestones, scientific data, regulatory interactions, and corporate actions that shape the company’s live biotherapeutics portfolio.
Seres Therapeutics (Nasdaq: MCRB) has announced participation in two virtual investor conferences. The Piper Sandler 32nd Annual Virtual Healthcare Conference will take place on December 1, 2020, featuring management in 1x1 meetings and a fireside chat available from November 23, 2020. The 3rd Annual Evercore ISI HealthCONx Virtual Conference is scheduled for December 2, 2020, also including management 1x1 meetings. Seres is a leader in microbiome therapeutics with advanced programs for recurrent C. difficile infection and ulcerative colitis.
Seres Therapeutics (MCRB) reported a net loss of $30.3 million for Q3 2020, up from $16.4 million in Q3 2019, primarily due to clinical and development expenses. The company announced that SER-109, its lead microbiome therapy, showed a 30.2% absolute reduction in recurrent C. difficile infections in its Phase 3 study, supporting its potential FDA approval. Following a successful capital raise, Seres has $320.3 million in cash, enhancing its growth prospects. Additionally, SER-287 and SER-301 are in clinical trials, advancing the company’s broad microbiome pipeline.
Seres Therapeutics (Nasdaq: MCRB) has initiated the dosing of participants in its Phase 1b trial for SER-301, aimed at treating active mild-to-moderate ulcerative colitis (UC). SER-301 is a microbiome therapeutic designed to counteract gastrointestinal inflammation and is based on insights from the earlier SER-287 trial. The study in Australia and New Zealand will involve 65 patients, focusing on safety and pharmacokinetics. Seres will receive a $10 million milestone payment from Nestlé Health Science upon trial initiation.
Seres Therapeutics (Nasdaq: MCRB) announced a conference call on November 9, 2020, at 8:30 a.m. ET to discuss Q3 2020 results and provide a business update. The SER-109 program has achieved significant clinical milestones, including Breakthrough Therapy and Orphan Drug designations from the FDA, targeting recurrent C. difficile infections. Additional programs like SER-287 and SER-401 are in various stages of clinical evaluation, with FDA designations indicating potential for innovation in microbiome therapeutics.
Seres Therapeutics (Nasdaq: MCRB) has expanded its leadership team by appointing David S. Ege as Executive Vice President and Chief Technology Officer, and Jayne M. Gansler as Executive Vice President and Chief People Officer. These appointments coincide with positive Phase 3 results for SER-109, which aims to be the first FDA-approved microbiome therapy. Previous leadership additions include Lisa von Moltke as Chief Medical Officer and Terri Young as Chief Commercial and Strategy Officer. The company is preparing for commercialization and enhancing its capabilities to support growth in the microbiome therapeutics space.
Seres Therapeutics (Nasdaq: MCRB) has announced positive Phase 3 results from the ECOSPOR III trial of SER-109, presented at the Virtual ACG Annual Meeting. The trial demonstrated a statistically significant reduction in C. difficile infection recurrence at 12 weeks post-treatment, with a 31.1% absolute risk reduction compared to placebo. The study included 182 patients and confirmed the therapy's efficacy across age groups. SER-109 aims to transform treatment for recurrent C. difficile infection, having received FDA Breakthrough Therapy and Orphan Drug designations.